The factor V activation paradox.
The prothrombinase complex consists of the protease factor Xa, Ca2+, and factor Va assembled on an anionic membrane. Factor Va functions both as a receptor for factor Xa and a positive effector of factor Xa catalytic efficiency and thus is key to efficient conversion of prothrombin to thrombin. The activation of the procofactor, factor V, to factor Va is an essential reaction that occurs early in the process of tissue factor-initiated blood coagulation; however, the catalytic sequence leading to formation of factor Va is a subject of disagreement. We have used biophysical and biochemical approaches to establish the second order rate constants and reaction pathways for the activation of phospholipid-bound human factor V by native and recombinant thrombin and meizothrombin, by mixtures of prothrombin activation products, and by factor Xa. We have also reassessed the activation of phospholipid-bound human prothrombin by factor Xa. Numerical simulations were performed incorporating the various pathways of factor V activation including the presence or absence of the pathway of factor V-independent prothrombin activation by factor Xa. Reaction pathways for factor V activation are similar for all thrombin forms. Empirical rate constants and the simulations are consistent with the following mechanism for factor Va formation. alpha-Thrombin, derived from factor Xa cleavage of phospholipid-bound prothrombin via the prethrombin 2 pathway, catalyzes the initial activation of factor V; generation of factor Va in a milieu already containing factor Xa enables prothrombinase formation with consequent meizothrombin formation; and meizothrombin functions as an amplifier of the process of factor V activation and thus has an important procoagulant role. Direct activation of factor V by factor Xa at physiologically relevant concentrations does not appear to be a significant contributor to factor Va formation.
Orfeo
Thomas
T
Department of Biochemistry, University of Vermont, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA.
Brufatto
Nicole
N
Nesheim
Michael E
ME
Xu
Hung
H
Butenas
Saulius
S
Mann
Kenneth G
KG
D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D004586:Electrophoresis; D004591:Electrophoresis, Polyacrylamide Gel; D004792:Enzyme Precursors / Q000737:chemistry; D005165:Factor V / Q000737:chemistry*; D015943:Factor Va / Q000737:chemistry; D015951:Factor Xa / Q000737:chemistry*; D006801:Humans; D007700:Kinetics; D008027:Light; D008956:Models, Chemical; D010743:Phospholipids / Q000737:chemistry; D017434:Protein Structure, Tertiary; D011516:Prothrombin / Q000096:biosynthesis / Q000737:chemistry; D011994:Recombinant Proteins / Q000737:chemistry; D012542:Scattering, Radiation; D013917:Thrombin / Q000737:chemistry; D013925:Thromboplastin / Q000737:chemistry*; D013997:Time Factors
D004792:Enzyme Precursors; D010743:Phospholipids; D011994:Recombinant Proteins; D015943:Factor Va; D005165:Factor V; D011516:Prothrombin; D013925:Thromboplastin; D013917:Thrombin; C026812:meizothrombin; D015951:Factor Xa